NEW DELHI: The Covid-19 Working Group of the NTAGI has advisable inclusion of the Serum Institute's Covovax within the nationwide vaccination programme for these aged 12 years and above, official sources mentioned on Sunday.
India's drug regulator had accredited Covovax for restricted use in emergency conditions in adults on December 28 and within the 12-17 age group, topic to sure situations, on March 9.
The Covid-19 Working Group has now advisable to the Standing Technical Sub-Committee of the Nationwide Technical Advisory Group on Immunisation (NTAGI) that Covovax be included within the nationwide vaccination programme for these aged 12 years and above, sources mentioned.
Serum Institute of India (SII) Director for Authorities and Regulatory Affairs Prakash Kumar Singh had written to the Union Well being Ministry lately, requesting for Covovax's inclusion within the immunisation drive.
"A gathering of the Covid-19 Working Group of the NTAGI happened on April 1 throughout which information of Covovax was reviewed, after which it advisable that the vaccine will be included within the nationwide Covid-19 vaccination programme for inoculating these aged 12 years and above," one of many sources mentioned.
Singh had acknowledged that the Pune-based agency needed to offer Covovax to personal hospitals at Rs 900 per dose plus GST and was ready for instructions to provide it to the Centre. Nevertheless, the value of the vaccine for the federal government was not talked about.
India started inoculating youngsters aged 12-14 from March 16. Organic E's Corbevax is getting used to inoculate them.
In a letter to Union Well being Secretary Rajesh Bhushan, Singh was learnt to have mentioned that non-public corporations, instructional institutes, social organisations, central authorities organisations and public sector undertakings had been making requests for Covovax to inoculate their staffers, households and kids.
"Underneath the visionary management of our CEO Adar C Poonawalla, now we have developed, manufactured and obtained emergency use authorisation from our nationwide regulatory authority for yet one more world-class Covid-19 vaccine, Covovax, for 18 years and above on December 28, and for kids within the age group of 12 to 17 years on March 9, 2022," an official supply quoted Singh as having written within the letter.